Oppenheimer Reiterates Outperform on Aldeyra Therapeutics, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Justin Kim has reiterated an Outperform rating on Aldeyra Therapeutics (NASDAQ:ALDX) and maintained a $14 price target.
August 09, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Justin Kim has reiterated an Outperform rating on Aldeyra Therapeutics and maintained a $14 price target.
The reiteration of an Outperform rating by Oppenheimer analyst Justin Kim indicates a positive outlook for Aldeyra Therapeutics. The maintained price target of $14 also suggests that the analyst believes the stock is undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100